Global Urothelial Cancer Drugs Market Outlook to 2023: Merck, Roche, Bristol-Myers Squibb, AstraZeneca, and Pfizer are Dominating - ResearchAndMarkets.com
The "Urothelial Cancer Drugs Market Size, Share & Trends Analysis Report By Treatment Class (Chemotherapy, Immunotherapy), By Major Markets, Competitive Landscape, And Segment Forecasts, 2018 - 2023" report has been added to ResearchAndMarkets.com's offering.
The global urothelial cancer drugs market size is expected to reach USD 3.6 billion by 2023, exhibiting a 22.9% CAGR during the forecast period.
Availability of novel drugs, presence of a strong pipeline, rising disease incidence, unhealthy lifestyle, and increasing awareness are driving this market.
Bladder transitional cell carcinoma (TCC) is the most common histology, accounting for nearly 90% of all urinary cancer cases.
- The U.S. dominated the urothelial cancer market, with more than 60% of the market in 2017. Several factors such as presence of a large target population, increased adoption of novel therapeutics, and multiple product launches will drive the market in this region.
- The therapeutic landscape is expected to witness a paradigm shift toward combination therapies and novel immuno-oncology products. Combination regimens, particularly checkpoint inhibitors, are likely to be introduced in the first-line setting. Immune checkpoint blockade therapy is expected to replace the current standard of care in bladder cancer in the foreseeable future.
- Therapeutic development in second-line setting for chemotherapy-intolerant patients is expected to have a major impact in the urothelial cancer space.
- Urothelial cancer presents a strong opportunity for introducing first-in-class treatments due to high unmet needs. Opportunities remain in the non-muscle invasive bladder cancer (NMIBC) setting where there exists an unmet need for treatment options for patients who are BCG-intolerant or ineligible.
Key Companies Profiled
- Bristol-Myers Squibb
Chapter 1 Research Methodology
Chapter 2 Executive Summary
Chapter 3 Disease Primer and Epidemiology
Chapter 4 Global Urothelial Cancer Drugs Market Overview
Chapter 5 Urothelial Cancer Drugs Market: Pipeline Intelligence
Chapter 6 Company Profiles
Chapter 7 Market Outlook
For more information about this report visit https://www.researchandmarkets.com/research/rp537m/global_urothelial?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20181031005327/en/